Trust Co. of Vermont Acquires Shares of 2,374 Labcorp Holdings Inc. $LH

Trust Co. of Vermont bought a new position in shares of Labcorp Holdings Inc. (NYSE:LH) in the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 2,374 shares of the medical research company’s stock, valued at approximately $665,000.

Several other large investors have also recently modified their holdings of LH. Hilton Head Capital Partners LLC purchased a new stake in shares of Labcorp during the 4th quarter valued at approximately $27,000. JPL Wealth Management LLC purchased a new position in Labcorp in the 3rd quarter valued at approximately $28,000. DV Equities LLC bought a new stake in Labcorp during the 4th quarter valued at $29,000. Allied Private Wealth LLC bought a new stake in Labcorp during the 2nd quarter valued at $33,000. Finally, EFG International AG purchased a new stake in shares of Labcorp during the fourth quarter worth $33,000. Hedge funds and other institutional investors own 95.94% of the company’s stock.

Labcorp Stock Down 0.2%

LH opened at $322.68 on Wednesday. The company has a fifty day moving average price of $288.51 and a 200-day moving average price of $275.48. The firm has a market capitalization of $26.17 billion, a P/E ratio of 26.69, a price-to-earnings-growth ratio of 1.84 and a beta of 0.87. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.80 and a quick ratio of 1.53. Labcorp Holdings Inc. has a one year low of $244.52 and a one year high of $329.47.

Labcorp (NYSE:LH) last issued its quarterly earnings data on Thursday, July 30th. The medical research company reported $4.99 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $4.78 by $0.21. The company had revenue of $3.73 billion for the quarter, compared to the consensus estimate of $3.71 billion. Labcorp had a return on equity of 16.74% and a net margin of 6.99%.The firm’s revenue was up 5.8% compared to the same quarter last year. During the same quarter last year, the business posted $4.35 earnings per share. Labcorp has set its FY 2026 guidance at 18.100-18.550 EPS. Equities research analysts expect that Labcorp Holdings Inc. will post 18.32 earnings per share for the current fiscal year.

Labcorp Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, September 11th. Shareholders of record on Friday, August 28th will be issued a $0.72 dividend. The ex-dividend date of this dividend is Friday, August 28th. This represents a $2.88 annualized dividend and a dividend yield of 0.9%. Labcorp’s dividend payout ratio (DPR) is presently 23.82%.

Insider Activity

In other news, EVP Kathryn W. Kyle sold 92 shares of the business’s stock in a transaction dated Thursday, July 2nd. The stock was sold at an average price of $286.19, for a total transaction of $26,329.48. Following the completion of the transaction, the executive vice president owned 3,904 shares of the company’s stock, valued at approximately $1,117,285.76. The trade was a 2.30% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, EVP Bryan T. Vaughn sold 234 shares of the company’s stock in a transaction that occurred on Thursday, July 2nd. The stock was sold at an average price of $286.19, for a total transaction of $66,968.46. Following the completion of the transaction, the executive vice president owned 6,746 shares in the company, valued at approximately $1,930,637.74. This trade represents a 3.35% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last quarter, insiders have sold 9,681 shares of company stock worth $3,027,677. Company insiders own 0.84% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms have recently commented on LH. Wall Street Zen raised Labcorp from a “hold” rating to a “buy” rating in a report on Sunday, July 12th. Barclays boosted their price objective on Labcorp from $290.00 to $320.00 and gave the company an “equal weight” rating in a research note on Thursday, July 30th. JPMorgan Chase & Co. raised their target price on Labcorp from $330.00 to $360.00 and gave the stock an “overweight” rating in a research note on Monday, August 3rd. Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating and set a $306.00 target price on shares of Labcorp in a report on Friday, July 31st. Finally, Weiss Ratings upgraded Labcorp from a “buy (b-)” rating to a “buy (b)” rating in a research report on Friday, July 24th. Nine analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $330.00.

Labcorp Profile

Laboratory Corporation of America Holdings, commonly known as Labcorp (NYSE: LH), is a global life sciences company that provides comprehensive clinical laboratory and drug development services. The company operates a broad network of laboratories, patient service centers and specialty testing sites to deliver diagnostic information and testing solutions that support patient care, clinical decision-making and population health initiatives.

Labcorp’s core businesses encompass clinical laboratory testing and pharmaceutical development services.